



HAL
open science

A machine learning derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: findings from the HOMAGE trial

Masatake Kobayashi, Olivier Huttin, João Pedro Ferreira, Kevin Duarte, Arantxa González, Stephane Heymans, Job A.J. Verdonschot, Hans-peter Brunner-la Rocca, Pierpaolo Pellicori, Andrew L Clark, et al.

► To cite this version:

Masatake Kobayashi, Olivier Huttin, João Pedro Ferreira, Kevin Duarte, Arantxa González, et al.. A machine learning derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: findings from the HOMAGE trial. European Journal of Heart Failure, 2023, 10.1002/ejhf.2859 . hal-04073025

HAL Id: hal-04073025

<https://hal.univ-lorraine.fr/hal-04073025>

Submitted on 18 Apr 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

A machine learning derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: findings from the HOMAGE trial

Running title: echocardiogram-based algorithm, cardiac structure, function and spironolactone

Masatake Kobayashi¹, Olivier Huttin¹, João Pedro Ferreira^{1,2}, Kevin Duarte¹, Arantxa González³, Stephane Heymans^{4,5}, Job A.J. Verdonschot⁶, Hans-Peter Brunner-La Rocca⁷, Pierpaolo Pellicori⁸, Andrew L Clark⁹, Johannes Petutschnigg¹⁰, Frank Edelmann¹⁰, John G Cleland⁸, Patrick Rossignol¹, Faiez Zannad¹, Nicolas Girerd¹, *on behalf of the HOMAGE Trial Committees and Investigators.*

1. Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, Inserm U1116, CHRU de Nancy and F-CRIN INI-CRCT, Nancy, France.
2. Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.
3. Program of Cardiovascular Diseases, CIMA. Universidad de Navarra and IdiSNA, Pamplona, Spain & CIBERCV, Carlos III Institute of Health, Madrid, Spain.
4. Department of Cardiology, Maastricht University, CARIM School for Cardiovascular Diseases, Universiteitssingel 50, 6229 ER Maastricht, Netherlands.
5. Centre for Molecular and Vascular Biology, Department of Cardiovascular Sciences, KU Leuven, Herestraat 49, bus 911, 3000 Leuven, Belgium.
6. Department of Cardiology, Maastricht University, CARIM School for Cardiovascular Diseases, Universiteitssingel 50, 6229 ER Maastricht, Netherlands
7. Department of Cardiology, Maastricht University, Maastricht, Netherlands.
8. School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow
9. Department of Cardiology, Hull University Teaching Hospitals NHS Trust, Castle Hill Hospital, Cottingham, East Riding of Yorkshire, UK.
10. Department of Internal Medicine and Cardiology Campus Virchow Klinikum, Charité University Medicine Berlin and German Centre for Cardiovascular research (DZHK), Berlin, Germany.

Corresponding Author: Nicolas Girerd

Centre d'Investigation Clinique 1433 module Plurithématique, CHRU Nancy - Hopitaux de Brabois, Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu, Nancy, 54500, France

Email: n.girerd@chru-nancy.fr

Total number of tables and figures: 1 table & 1 figure

Financial Disclosure: The research leading to these results has received funding from the European Union Commission's Seventh Framework program under grant agreement N° 305507 (HOMAGE).

Keywords; Heart failure, echocardiogram, collagen, spironolactone, biomarkers

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the [Version of Record](#). Please cite this article as doi: [10.1002/ejhf.2859](https://doi.org/10.1002/ejhf.2859)

Background

Cardiac dysfunction often exists and progresses for years before the onset of clinical heart failure (HF) ¹. Echocardiographic screening for abnormalities of cardiac structure or function in asymptomatic individuals may predict the future development of HF ^{2,3}. However, widely accepted echocardiogram-based diagnostic algorithms for assessment of cardiac abnormalities are not yet established as tools to risk-stratify patients at risk of future HF.

In a recent report, we used a machine learning approach fueled by echocardiographic variables to develop an algorithm (the e'VM algorithm) which characterizes asymptomatic individuals with distinct cardiac structure and function, different proteomic data, and differing long-term risk of developing HF ⁴. However, the study was conducted in a relatively young population with a low comorbidity burden. It is not clear whether this e'VM algorithm provides appropriate information in individuals at high risk of developing HF. In addition, whether the e'VM echocardiographic phenotypes identifies patients more likely to benefit from preventive treatment (such as mineralocorticoid receptor antagonists [MRA]) is unknown.

The Heart “OMics” in AGEing” (HOMAGE) trial evaluated the effect of spironolactone (an MRA) in patients at risk of HF. It provides a unique opportunity to explore whether the e'VM algorithm identifies asymptomatic individuals with different biological profiles and who may benefit from spironolactone treatment ⁵.

Aims

In the present analysis, we explored whether the e'VM algorithm identified patients at risk of HF with different characteristics who had different responses to spironolactone treatment.

Methods

The design and main results of the HOMAGE trial have previously been reported^{5, 6}. Briefly, the HOMAGE trial was a randomized placebo-controlled, double-blind trial, assigning 527 patients at high risk of HF to receive either spironolactone or placebo for up to 9 months. The current post-hoc analysis included the 416 participants who had available the echocardiographic variables which are incorporated in an echocardiography algorithm (*i.e.*, e' mean, left ventricular end-diastolic volume-index [LVEDVi] and left ventricular mass-indexed [LVMI]; e'VM algorithm). To classify e'VM phenotypes, participants were first split by e' mean: if e' mean was <10 cm/s, patients were categorized by a combination of thresholds for LVEDVi and LVMI. Phenotypes were labeled: a) mostly normal (MN); b) diastolic changes (D); and c) diastolic changes with structural remodeling (D/S) as shown in *Supplemental Figure 1*⁴. As a mean age of patients in the HOMAGE trial is higher than those in the Suivi Temporaire Annuel Non-Invasif de la Santé des Lorrains Assurés Sociaux (STANISLAS) cohort (from which the e'VM algorithm was derived), the thresholds for e' mean, LVEDVi and LVMI were modified by age using decade-specific limits (*Supplemental Table 1*).

Echocardiograms were analyzed offline by a single experienced operator, blinded to clinical data, using dedicated software (Echo PAC, GE Healthcare) as recently recommended^{7, 8}. Measurement reproducibility has been reported⁹. Procollagen type I C-terminal propeptide (PICP) was measured by enzyme immune-assay (METRA; Quidel Corporation®), procollagen type III N-terminal propeptide (PIIINP) and collagen type I C-terminal telopeptide (CITP) by radio-immunoassay (Orion Diagnostica®), galectin-3 by enzyme-linked immunosorbent assay (ELISA) (BG Medicine®), N-terminal pro-b-type natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hsTnT) and growth differentiation factor 15 (GDF-15) by electro-chemiluminescence (ELECSYS® 2010 analyser; Roche Diagnostics, Mannheim, Germany), and b-

type natriuretic peptide [BNP] by using Olink Proseek® Multiplex cardiovascular II, blinded to clinical data and randomization.

Categorical variables are presented as frequencies (percentages) and continuous variables as median (25th and 75th percentiles). Comparisons of baseline characteristics across echocardiographic phenotypes were analyzed using analysis of variance, Kruskal-Wallis and χ^2 tests, as appropriate. Analysis of covariance was used for changes in echocardiographic and biomarker variables by the effect of spironolactone after adjustment for age, sex, body mass index (BMI), a prevalence of hypertension, diabetes and estimated glomerular filtration rate. Interaction between spironolactone effect and echocardiographic phenotypes on changes in echocardiographic variables and circulating biomarkers was assessed. Statistical analyses were performed using R version 4.0.2 (R Development Core Team, Vienna, Austria). A two-sided p-value <0.05 was considered statistically significant.

Results

The 416 participants included in the present analysis had a similar profile to those included in HOMAGE (data not shown) with a median age of 73 years (25th and 75th centiles 69-78); 24.5% were women (*Table 1*).

Age, BMI, cardiovascular risk factors/diseases (*i.e.*, hypertension, coronary artery disease and renal function) were similar across e'VM phenotypes except for a lower prevalence of diabetes in the MN phenotype, a higher number of women in the D phenotype and higher systolic blood pressure (BP) in the D/S phenotype (p-values<0.05). The D phenotype represented half of the participants (N=200, 48%), and had the smallest LV and LA volumes. The D/S phenotype (N=147) had the highest LV mass, volumes, LA volumes indexed by body surface area (LAV_i), lowest LVEF (despite having a mean LVEF of 60%), and lowest e' as well as highest E/e' (*Table 1*).

Echocardiographic strain parameters for LV and LA were not significantly different across e'VM phenotypes (p-values>0.10) (*Table 1*).

Patients with D/S phenotype had the highest serum concentrations of NTproBNP, BNP, troponin-T and high-sensitivity troponin-T (all p-values<0.05). PICP, CITP, PIIINP, GDF-15 and galectin-3 did not differ between phenotypes (*Table 1*).

During the 9-month period, spironolactone effect on E/e', NTproBNP and BNP was more pronounced in people with the D/S phenotype versus those with the D phenotype (p for interaction<0.05 for all, *Figure 1 & Supplemental Table 2*). When considering guideline-recommended echocardiographic variables defined by the 2016 ASE/EACVI, namely, diastolic dysfunction (DD), left ventricular hypertrophy (LVH, >95g/m² in women and >115g/m² in men), left atrial (LA) enlargement (>34ml/m²), abnormal e' by a septal e' <7cm/sec or lateral e' <10cm/sec, and increased E/e' (>14)^{7, 10}, we found no significant interaction with MRA response, except for a more pronounced reduction of NT-proBNP and BNP in patients who had a LA enlargement (p for interaction <0.05). The magnitude of the effect of spironolactone on serum PICP was higher in the D/S phenotype (delta, -12.6, 95%CI, -20.5 to -4.8, p=0.002) than in the D phenotype (delta, -6.3, 95%CI, -12.2 to -0.4, p=0.04) although this differential effect did not reach significance (p for interaction=0.21) (*Figure 2*). Significant decreases in LVMi and LAVi were also observed only in the D/S phenotype (p for interaction>0.10). The effect of spironolactone on LVEDVi, systolic BP and PIIINP was similar across the 3 phenotypes (*Supplemental Table 2*).

Discussion

In the present analysis of the HOMAGE trial, we report that our e'VM classification system derived from echocardiographic data using a machine learning-based algorithm identified subgroups of people at risk of developing HF with different echocardiographic variables, circulating biomarkers of cardiac stress and damage and of collagen metabolism, and

Accepted Article

response to spironolactone. Specifically, people with the D and D/S phenotypes had higher levels of E/e', and those with the D/S phenotype had greater structural remodeling of the left ventricle and atrium as well as higher levels of circulating biomarkers reflecting congestion (*i.e.*, natriuretic peptides) and myocardial damage (*i.e.*, troponin). The magnitude of the antifibrotic and anti-remodeling effects of spironolactone was more pronounced in the D/S phenotype. These findings underscore the potential value of the e'VM classification for screening asymptomatic, but at-risk, individuals and for identifying those more likely to benefit from spironolactone, which might prevent or delay the onset of HF.

The e'VM algorithm significantly predicted MRA response on E/e', BNP and NT-ProBNP, whereas guideline-recommended DD classification, LVH, abnormal e' or increased E/e' did not. The favorable effects of spironolactone were more pronounced in D/S phenogroup. The changes in collagen peptides were also more pronounced in the D/S phenotype, but it did not reach statistical significance. These results suggested that, even in patients prior to the onset of HF, those who had cardiac structure and function remodeling were more likely to experience antifibrotic and natriuretic effects of spironolactone, which is also supported by prior reports^{11,12}. In addition, interestingly, we observed a significant interaction between LA enlargement and MRA response on natriuretic peptides, which may be partly supported by the natriuretic effect of spironolactone¹³; however, no significant interaction was identified with E/e'.

Studies examining the impact of mineralocorticoid antagonist therapy on cardiac structure and function in HF with preserved ejection (HFpEF) have yielded conflicting results¹⁴. In the Aldosterone Receptor Blockage in Diastolic Heart Failure (Aldo-DHF) trial (N=442), patients assigned to receive spironolactone had a greater fall in LV mass and improvement in diastolic function compared to those with placebo¹⁵. By contrast, in a sub-study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial (N=239), neither cardiac structural nor functional remodeling was affected by

spironolactone as compared with placebo¹⁶. The population enrolled in the HOMAGE trial had similar abnormalities of LV and LA structure and diastolic function as those in large clinical trials of HFpEF⁵. Therefore, our results showing a favorable effect of spironolactone treatment predominantly in the D/S phenotype suggest that the e'VM classification can identify a subgroup in the preclinical HFpEF category whose impaired cardiac structure and function are more likely to improve with spironolactone treatment. The results further suggest that the benefit from spironolactone is more likely in patients with some degrees of cardiac structural and functional abnormalities, which may eventually be useful to guide preventive strategies in the future.

The main limitation of the current study was post-hoc nature, a relatively moderate sample sized, and should be regarded as hypothesis-generating; thus, prospective validation with a dedicated trial is warranted to ascertain whether the e'VM-based classification predicts MRA response. Eventually, an e'VM classification-guided preventive HF trial would be worthy of investigation to ascertain whether this new echocardiographic classification can be applied to identify individuals at risk of HF, and those who are more likely to require early initiation of specific disease modifying agents. Age based cut-offs, in addition, were supported by prior studies but not guidelines^{17, 18}. Lastly, we cannot completely rule-out early stages of cardiac amyloidosis in some patients enrolled in the trial.

In conclusion, in the HOMAGE trial, the e'VM classification system identified asymptomatic subgroups with distinct abnormalities of cardiac structure and function that are more likely to have chronically elevated filling pressures and myocardial damage/injury. The magnitude of the effects of spironolactone on these cardiac abnormalities and circulating biomarkers differed with classification. These findings may support the use of the e'VM algorithm to identify participants at higher risk of HF and guide preventive HF treatment.

References

1. Cleland JGF, Pellicori P and González A. A novel treatment for heart failure targets myocardial fibrosis. *Nature medicine*. 2021;27:1343-1344.
2. Vasani RS, Xanthakis V, Lyass A, Andersson C, Tsao C, Cheng S, Aragam J, Benjamin EJ and Larson MG. Epidemiology of Left Ventricular Systolic Dysfunction and Heart Failure in the Framingham Study: An Echocardiographic Study Over 3 Decades. *JACC: Cardiovascular Imaging*. 2018;11:1-11.
3. Kosmala W and Marwick TH. Asymptomatic Left Ventricular Diastolic Dysfunction. *JACC: Cardiovascular Imaging*. 2020;13:215-227.
4. Kobayashi M, Huttin O, Magnusson M, Ferreira JP, Bozec E, Huby AC, Preud'homme G, Duarte K, Lamiral Z, Dalleau K, Bresso E, Smaïl-Tabbone M, Devignes MD, Nilsson PM, Leosdottir M, Boivin JM, Zannad F, Rossignol P and Girerd N. Machine Learning-Derived Echocardiographic Phenotypes Predict Heart Failure Incidence in Asymptomatic Individuals. *JACC Cardiovasc Imaging*. 2021.
5. Pellicori P, Ferreira JP, Mariotoni B, Brunner-La Rocca HP, Ahmed FZ, Verdonchot J, Collier T, Cuthbert JJ, Petutschnigg J, Mujaj B, Girerd N, González A, Clark AL, Cosmi F, Staessen JA, Heymans S, Latini R, Rossignol P, Zannad F and Cleland JGF. Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. *Eur J Heart Fail*. 2020;22:1711-1723.
6. Cleland JGF, Ferreira JP, Mariotoni B, Pellicori P, Cuthbert J, Verdonchot JAJ, Petutschnigg J, Ahmed FZ, Cosmi F, Brunner La Rocca HP, Mamas MA, Clark AL, Edelmann F, Pieske B, Khan J, McDonald K, Rouet P, Staessen JA, Mujaj B, González A, Diez J, Hazebroek M, Heymans S, Latini R, Grojean S, Pizard A, Girerd N, Rossignol P, Collier TJ and Zannad F. The effect of spironolactone on cardiovascular function and markers

of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial. *European heart journal*. 2021;42:684-696.

7. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, 3rd, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK, Popescu BA and Waggoner AD. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2016;29:277-314.
8. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK and Schiller NB. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. *J Am Soc Echocardiogr*. 2010;23:685-713; quiz 786-8.
9. Frikha Z, Girerd N, Huttin O, Courand PY, Bozec E, Olivier A, Lamiral Z, Zannad F and Rossignol P. Reproducibility in echocardiographic assessment of diastolic function in a population based study (the STANISLAS Cohort study). *PLoS One*. 2015;10:e0122336.
10. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W and Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2015;28:1-39.e14.
11. Zannad F, Alla F, Dousset B, Perez A and Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with

congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. *Circulation*. 2000;102:2700-6.

12. Ravassa S, López B, Ferreira JP, Girerd N, Bozec E, Pellicori P, Mariotoni B, Cosmi F, Hazebroek M, Verdonschot JAJ, Cuthbert J, Petutschnigg J, Moreno MU, Heymans S, Staessen JA, Pieske B, Edelmann F, Clark AL, Cleland JGF, Zannad F, Díez J and González A. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial. *European journal of heart failure*. 2022;24:321-331.

13. Inciardi RM, Bonelli A, Biering-Sorensen T, Cameli M, Pagnesi M, Lombardi CM, Solomon SD and Metra M. Left atrial disease and left atrial reverse remodelling across different stages of heart failure development and progression: a new target for prevention and treatment. *European journal of heart failure*. 2022;24:959-975.

14. Ferreira JP, Cleland JG, Girerd N, Bozec E, Rossignol P, Pellicori P, Cosmi F, Mariotoni B, Solomon SD, Pitt B, Pfeffer MA, Shah AM, Petutschnigg J, Pieske B, Edelmann F and Zannad F. Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials. *European journal of heart failure*. 2022.

15. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Löffler M, Düngen HD, Tschöpe C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G and Pieske B. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. *Jama*. 2013;309:781-91.

16. Shah AM, Claggett B, Sweitzer NK, Shah SJ, Deswal A, Anand IS, Fleg JL, Pitt B, Pfeffer MA and Solomon SD. Prognostic Importance of Changes in Cardiac Structure and

Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. *Circulation Heart failure*. 2015;8:1052-1058.

17. Nayor M, Cooper LL, Enserro DM, Xanthakis V, Larson MG, Benjamin EJ, Aragam J, Mitchell GF and Vasan RS. Left Ventricular Diastolic Dysfunction in the Community: Impact of Diagnostic Criteria on the Burden, Correlates, and Prognosis. *Journal of the American Heart Association*. 2018;7:e008291.

18. Hung CL, Gonçalves A, Shah AM, Cheng S, Kitzman D and Solomon SD. Age- and Sex-Related Influences on Left Ventricular Mechanics in Elderly Individuals Free of Prevalent Heart Failure: The ARIC Study (Atherosclerosis Risk in Communities). *Circ Cardiovasc Imaging*. 2017;10.

Figure 1. Change in echocardiographic variables, blood pressure and biomarkers in response to spironolactone according to the e'VM phenotypes


Panel A presents the changes in LVMi, LAVi, E/e' and SBP over 9 months between spironolactone/placebo groups according to the e'VM classification. Panel B presents the changes in collagen biomarkers (type III and I collagen [PIIINP and PICP]) and natriuretic peptide (i.e., NT-proBNP and BNP) over 9 months between spironolactone/placebo groups according to the e'VM classification.

P-values were adjusted for age, sex, body mass index, a prevalence of hypertension, diabetes mellitus, glomerular filtration rate and baseline echocardiographic/proteomic variables.

Abbreviations are presented in *Table 1*.

Figure 1. Change in echocardiographic variables, blood pressure and biomarkers in response to spironolactone according to the e'VM phenotypes

A.



B.







Table 1. Clinical characteristics according to the e'VM echocardiographic phenotypes

Values are expressed as mean \pm SD, n (%) or median (25th to 75th percentile)

MN, mostly normal; D, diastolic changes; D/S, diastolic changes with structural remodeling; BMI, body mass index; TIA, transient ischemic attack; COPD, chronic obstructive pulmonary disease; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; BP, blood pressure; eGFR, estimated glomerular filtration rate; LVEDVi, left ventricular end-diastolic volume index; LVEF, left ventricular ejection fraction; LVMi, left ventricular mass index; LAVi, left atrial volume index; GLS, global longitudinal strain; PIIINP, procollagen type-III N-terminal propeptide; PICP, procollagen type-I C-terminal propeptide; CITP, collagen type-I C-terminal telopeptide; GDF-15, growth differentiation factor-15; NT-proBNP, N-terminal pro-B-type natriuretic peptide; BNP, B-type natriuretic peptide; NPX, normalized protein expression.

Accepted Article

Table 1. Clinical characteristics according to the e'VM echocardiographic phenotypes

	Overall (N=416)	MN type (N=66)	D type (N=200)	D/S type (N=150)	p- value
Age, years	74 ± 7	74 ± 6	73 ± 6	74 ± 7	0.96
Women, N (%)	102 (24.5 %)	11 (16.7 %)	62 (31.0 %)	29 (19.3 %)	0.012
BMI, kg/m ²	29 ± 5	28 ± 5	28 ± 5	29 ± 5	0.34
Smoking, N (%)	32 (7.7 %)	4 (6.1 %)	13 (6.5 %)	15 (10.0 %)	0.41
Medical history, N (%)					
Hypertension	321 (77.2 %)	51 (77.3 %)	147 (73.5 %)	123 (82.0 %)	0.17
Diabetes	172 (41.3 %)	16 (24.2 %)	91 (45.5 %)	65 (43.3 %)	0.008
Coronary artery disease	299 (71.9 %)	52 (78.8 %)	142 (71.0 %)	105 (70.0 %)	0.39
Myocardial infarction	166 (39.9 %)	25 (37.9 %)	76 (38.0 %)	65 (43.3 %)	0.56
Stroke or TIA	19 (4.6 %)	3 (4.5 %)	7 (3.5 %)	9 (6.0 %)	0.54
OPD	23 (5.5 %)	5 (7.6 %)	13 (6.5 %)	5 (3.3 %)	0.32
Medications, N (%)					
ACEi or ARB	326 (78.4 %)	54 (81.8 %)	156 (78.0 %)	116 (77.3 %)	0.75
Beta-blocker	293 (70.4 %)	46 (69.7 %)	138 (69.0 %)	109 (72.7 %)	0.75
CCB	83 (20.0 %)	16 (24.2 %)	34 (17.0 %)	33 (22.0 %)	0.33
Lipid-lowering therapy	342 (82.2 %)	54 (81.8 %)	166 (83.0 %)	122 (81.3 %)	0.92
Antiplatelet	337 (81.0 %)	57 (86.4 %)	156 (78.0 %)	124 (82.7 %)	0.26
Clinical profile					
Systolic BP, mmHg	143 ± 21	139 ± 21	141 ± 20	146 ± 21	0.034
Heart rate, bpm	62 ± 9	61 ± 10	62 ± 9	61 ± 9	0.47
Laboratory data					
Hemoglobin, g/dl	14.0 ± 1.4	14.0 ± 1.4	14.0 ± 1.3	13.9 ± 1.4	0.86
Sodium, mmol/l	139.1 ± 2.9	138.6 ± 3.5	138.8 ± 2.8	139.7 ± 2.5	0.003
Potassium, mmol/l	4.3 ± 0.4	4.3 ± 0.4	4.4 ± 0.4	4.3 ± 0.4	0.44
eGFR, ml/min/1.73m ²	71 ± 16	69 ± 16	71 ± 16	72 ± 16	0.63
Echocardiographic variables					
LVEDVi, ml/m ²	43 ± 11	44 ± 10	38 ± 8	49 ± 11	<0.001
LVEF, %	62 ± 7	62 ± 6	63 ± 7	60 ± 8	0.001
LVMi, g/m ²	98 ± 27	93 ± 27	84 ± 15	120 ± 25	<0.001
LVMi >115ml/m ² in men or LVMi >95ml/m ² in women, N (%)	121 (29.2 %)	15 (23.4 %)	19 (9.5 %)	87 (58.0 %)	<0.001
LAVi, ml/m ²	32 ± 9	34 ± 10	29 ± 7	35 ± 10	<0.001
LAVi >34ml/m ² , N (%)	141 (34.4 %)	26 (41.3 %)	41 (20.7 %)	74 (49.7 %)	<0.001
E/e' ratio	0.9 ± 0.3	1.1 ± 0.4	0.9 ± 0.3	0.8 ± 0.3	<0.001
e' lateral, cm/s	8.7 ± 2.8	12.8 ± 2.6	8.2 ± 2.0	7.7 ± 2.3	<0.001
e' septal, cm/s	6.0 ± 1.7	7.9 ± 1.9	5.9 ± 1.4	5.4 ± 1.3	<0.001
e' septal <7cm/s or e' lateral <10cm/s, N (%)	354 (85.3 %)	21 (32.3 %)	187 (93.5 %)	146 (97.3 %)	<0.001
E/e' mean	9.8 ± 3.3	7.6 ± 2.1	10.0 ± 3.1	10.5 ± 3.6	<0.001
E/e' mean >14, N (%)	40 (9.8 %)	1 (1.5 %)	19 (9.6 %)	20 (13.7 %)	0.022
Echocardiographic strain					
GLS, % (N=73)	-17.8 ± 2.4	-18.4 ± 2.7	-17.9 ± 2.3	-17.0 ± 2.7	0.26
LA reservoir strain, % (N=111)	24.8 ± 4.8	24.4 ± 4.4	24.9 ± 5.2	24.8 ± 4.2	0.92
LA conduit strain, % (N=111)	10.4 ± 3.5	10.6 ± 3.1	10.4 ± 3.5	10.4 ± 4.1	0.98
LA contractile strain, % (N=111)	14.4 ± 3.9	13.9 ± 3.5	14.5 ± 4.1	14.4 ± 3.8	0.80
Biomarker profiles					
PIIINP, µg/L	3.9 (3.1 - 5.0)	3.9 (3.2 - 5.1)	3.8 (3.0 - 4.9)	4.1 (3.0 - 5.3)	0.27
PICP, µg/L	79.4 (64.7 - 96.0)	77.7 (62.5 - 92.2)	76.9 (63.2 - 93.2)	81.7 (68.1 - 99.7)	0.12
CITP, µg/L	3.7 (2.8 - 4.8)	3.5 (2.9 - 4.6)	3.7 (2.8 - 4.9)	3.7 (2.8 - 4.8)	0.99
GDF 15, ng/L	1434 (1061 - 2148)	1449 (963 - 1878)	1398 (1049 - 2174)	1466 (1092 - 2338)	0.28
Galectin-3, µg/L	16.2 (13.5 - 20.0)	15.4 (12.9 - 19.5)	16.2 (13.1 - 19.6)	16.6 (14.1 - 20.7)	0.13
NT-proBNP, pg/ml	208 (134 - 342)	166 (125 - 289)	201 (128 - 329)	247 (150 - 450)	0.003
BNP (NPX)	2.7 ± 1.1	2.6 ± 1.2	2.6 ± 1.0	2.9 ± 1.2	0.046
High-sensitivity troponin-T, ng/L	12.8 (8.9 - 18.1)	12.1 (8.8 - 16.6)	12.0 (8.0 - 17.0)	14.2 (10.1 - 19.4)	0.007